The US FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The medication comes in two formulations: a weekly and a monthly version. The adverse reactions include headache, constipation, nausea, injection-site erythema, injection-site pruritus, insomnia & UTI.